Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide + Insulin in T2DM and NAFLD
NCT01006889Phase 4Completed
- Sponsor
- University of Florida
- Start
- Jan 2008
- Primary completion
- Dec 2009
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of exenatide in type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD), sponsored by University of Florida. Primary endpoint: Hepatic Steatosis at 6 months. Started Jan 2008; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT01006889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01006889.